These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 29464356)

  • 1. Weighing the Anti-Ischemic Benefits and Bleeding Risks from Aspirin Therapy: a Rational Approach.
    Dugani S; Ames JM; Manson JE; Mora S
    Curr Atheroscler Rep; 2018 Feb; 20(3):15. PubMed ID: 29464356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aspirin for Primary Prevention of Atherosclerotic Cardiovascular Disease: Advances in Diagnosis and Treatment.
    Mora S; Manson JE
    JAMA Intern Med; 2016 Aug; 176(8):1195-204. PubMed ID: 27322595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.
    Flaker GC; Gruber M; Connolly SJ; Goldman S; Chaparro S; Vahanian A; Halinen MO; Horrow J; Halperin JL;
    Am Heart J; 2006 Nov; 152(5):967-73. PubMed ID: 17070169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials.
    Berger JS; Roncaglioni MC; Avanzini F; Pangrazzi I; Tognoni G; Brown DL
    JAMA; 2006 Jan; 295(3):306-13. PubMed ID: 16418466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on aspirin in the treatment and prevention of cardiovascular disease.
    Hennekens CH
    Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The aspirin controversy in primary prevention.
    Raju NC; Eikelboom JW
    Curr Opin Cardiol; 2012 Sep; 27(5):499-507. PubMed ID: 22874127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.
    Reaume KT; Regal RE; Dorsch MP
    Ann Pharmacother; 2008 Apr; 42(4):550-7. PubMed ID: 18319394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aspirin in the primary prevention of cardiovascular disease: current knowledge and future research needs.
    Hennekens CH; Dalen JE
    Trends Cardiovasc Med; 2014 Nov; 24(8):360-6. PubMed ID: 25444455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses.
    Hennekens CH; Sacks FM; Tonkin A; Jukema JW; Byington RP; Pitt B; Berry DA; Berry SM; Ford NF; Walker AJ; Natarajan K; Sheng-Lin C; Fiedorek FT; Belder R
    Arch Intern Med; 2004 Jan; 164(1):40-4. PubMed ID: 14718320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable.
    Connolly SJ; Eikelboom JW; Ng J; Hirsh J; Yusuf S; Pogue J; de Caterina R; Hohnloser S; Hart RG;
    Ann Intern Med; 2011 Nov; 155(9):579-86. PubMed ID: 22041946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on aspirin in the treatment and prevention of cardiovascular disease.
    Hennekens CH
    Am Heart J; 1999 Apr; 137(4 Pt 2):S9-S13. PubMed ID: 10097241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.
    Ridker PM; Cook NR; Lee IM; Gordon D; Gaziano JM; Manson JE; Hennekens CH; Buring JE
    N Engl J Med; 2005 Mar; 352(13):1293-304. PubMed ID: 15753114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aspirin for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: A Decision Analysis for the U.S. Preventive Services Task Force.
    Dehmer SP; Maciosek MV; Flottemesch TJ; LaFrance AB; Whitlock EP
    Ann Intern Med; 2016 Jun; 164(12):777-86. PubMed ID: 27064573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks.
    Aguilar M; Hart R
    Cochrane Database Syst Rev; 2005 Oct; (4):CD001925. PubMed ID: 16235290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspirin for primary prevention of cardiovascular disease events.
    Nemerovski CW; Salinitri FD; Morbitzer KA; Moser LR
    Pharmacotherapy; 2012 Nov; 32(11):1020-35. PubMed ID: 23019080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiplatelet therapy in acute coronary syndrome and atrial fibrillation: aspirin.
    Tanguay JF
    Adv Cardiol; 2012; 47():20-30. PubMed ID: 22906900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials.
    Kunutsor SK; Seidu S; Khunti K
    Diabet Med; 2017 Mar; 34(3):316-327. PubMed ID: 27086572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials.
    Berger JS; Krantz MJ; Kittelson JM; Hiatt WR
    JAMA; 2009 May; 301(18):1909-19. PubMed ID: 19436018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The rise and fall of aspirin in the primary prevention of cardiovascular disease.
    Raber I; McCarthy CP; Vaduganathan M; Bhatt DL; Wood DA; Cleland JGF; Blumenthal RS; McEvoy JW
    Lancet; 2019 May; 393(10186):2155-2167. PubMed ID: 31226053
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.